Accelerating animal-free drug pipelines with organ-on-a-chip technology
June 23, 2025 – 16:00 BST / 17:00 CEST / 11:00 EDT / 08:00 PDT
Animal models within the realms of therapeutic testing have limited predictive value, which poses a significant challenge and raises concerns about their broader use in basic research. Therefore, welcoming new approaches to produce human-relevant data is essential for improving translational success and advancing our understanding of human biology.
Join Emulate’s Dr. Lorna Ewart, Chief Scientific Officer and Dr. Daniel Levner, Chief Technology Officer, as they share the predictive power of organ-on-a-chip. Discover how this next-generation technology can be used for toxicology testing to support your drug development efforts by seamlessly integrating into your existing workflow and project a quantifiable ROI from faster data.
Key learning objectives
- Explore the latest global initiatives encouraging reduced reliance on animal testing and their impact on drug development strategies and regulatory submissions.
- Discover key milestones in Emulate’s collaborations with regulation agencies to establish organ-on-a-chip technology.
- Learn how Emulate’s current and upcoming platforms align with evolving regulatory expectations worldwide and help future-proof your drug development pipeline against shifting standards in animal testing.
Who should attend?
- Executives, lab managers, scientists and end users working in the pharma and biopharma industry
- Academics such as professors, assistant professors and post-docs
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.
Speakers
Dr. Lorna Ewart, is Chief Scientific Officer at Emulate, steering the company’s scientific strategy and biological R&D, drawing on 20 + years in bioscience and drug safety. Prior to Emulate, at AstraZeneca she founded the Microphysiological Systems Centre of Excellence, leading industry adoption of Organ-Chips, and later ran Veroli Consulting, advising academia, biotech, and pharma on OrganChip and organoid technologies. A classically trained pharmacologist, she has 35+ publications and is a Fellow of the Royal Society of Biology and British Pharmacological Society.
Dr. Daniel Levner holds a PhD in electrical engineering and an MS in aeronautics from Stanford, and lists 70+ patents. At present, he is the Chief Technology Officer and co-founder of Emulate, where he directs development and commercialization of the OrganChips platform. Formerly a Senior Staff Scientist at Harvard’s Wyss Institute, he led the engineering team that united biology, engineering, and business to launch the technology. Dr. Levner previously collaborated with Prof. George Church on advanced diagnostics and sequencing, and earlier founded start-ups in medical diagnostics and optical telecom.
Moderator
